Therapy Areas: Oncology
CANbridge Pharmaceuticals and GC Pharma Ink Greater China Licensing Agreement for Hunterase for Hunter Syndrome
9 January 2019 - - Chinese biopharmaceutical company CANbridge Pharmaceuticals Inc. and South Korea-based GC Pharma (formerly known as Green Cross Corp.) (KRX:006280), have inked an exclusive licensing agreement in the greater China area to commercialise Hunterase, a human recombinant iduronate-2-sulfatase enzyme replacement therapy for the treatment of Hunter syndrome. Developed by GC Pharma, Hunterase is marketed in more than ten countries worldwide, the company said.

There is no approved treatment for Hunter syndrome in China, unlike in some parts of the world.

Hunter syndrome (Mucopolysaccharidosis type II) is an inherited lysosomal storage disease that occurs primarily in boys. It causes an enzyme deficiency that interferes with the body's ability to break down certain complex sugars, resulting in serious skeletal, tissue, neurological and multi-organ complications and, ultimately, death.

It occurs in approximately 1.3 out of 100,000 male newborns.

There is no cure. The standard treatments are enzyme replacement therapy or palliative care. Mucopolysaccharidosis is one of the 121 diseases on the China Rare Disease List recently published by the Chinese government.

GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines.

Headquartered in South Korea, GC Pharma is one of the largest protein products manufacturers in the world and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corp. updates its corporate brand as GC Pharma in early 2018.

Green Cross Corp. remains the company's registered, legal name.

CANbridge Pharmaceuticals is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.

The company is a specialist in orphan diseases in China, and has a partnership with WuXi Biologics to develop and commercialise proprietary therapeutics for the treatment of rare diseases.

CANbridge also has exclusive rights to develop and commercialise Puma biotechnology's Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and commercialise APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology's ErbB3 inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to commercialise Caphosol for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.